Amgen reported strong third-quarter results with significant growth in international sales and key products, alongside improved operating margins and raised 2014 guidance. Management's focus on R&D and strategic expansions, despite upcoming patent challenges, indicates continued positive momentum. The optimistic outlook is likely to bolster investor confidence in the short term.

[1]